BPC-157, Different Salt
Pentadeca arginate
Also known as PDA · Arg-BPC · BPC-157 arginate salt · Pentadecapeptide arginate
At a glance
- What it is
- The same 15-amino-acid peptide as BPC-157, supplied as an arginine salt.
- Evidence
- Practitioner experience onlyHow the tiers workPentadeca arginate is BPC-157 with a different salt. Why this tier
- Half-life
- Not established in available literature
- Routes
- Subcutaneous, Oral
- Category
- Healing
- WADA
- Prohibited by interpretation (S0)
- Amino acids
- 15
Putting Pentadeca arginate on a schedule, with the vial it comes from and a log of each dose, happens in the app: Claritide for iPhone.
Why this tier
Pentadeca arginate is BPC-157 with a different salt. The arginate salt is genuinely more chemically stable in a vial and in acid. That comes from a 2017 patent filed by the company that owns it, not from a study. Nothing has ever been tested on a human, or on an animal, as pentadeca arginate. Every biological claim made for it is borrowed from BPC-157 rodent research, and BPC-157’s only human efficacy data is a single 53-patient abstract that did not reach statistical significance.
What it is
Pentadeca arginate is BPC-157 with a different counterion. The peptide is identical, the same 15 amino acids in the same order, supplied as an L-arginine salt instead of an acetate salt. The arginate is genuinely more stable in a vial and in acid, and that comes from a patent filed by the company that owns it, not from a study. Nothing has ever been tested on a human, or on an animal, as pentadeca arginate.
How it works
There is no separate mechanism to describe, and that is the record. PDA is the pentadecapeptide GEPPPGKPADDAGLV, BPC-157, paired with arginine instead of acetate. A counterion changes how a salt crystallises, dissolves and survives storage; it does not change what the peptide does once it is in solution and in the body. Every biological claim made for pentadeca arginate is borrowed wholesale from BPC-157 rodent work: increased VEGFR2 expression and angiogenesis, nitric oxide system modulation, growth hormone receptor upregulation in tendon fibroblasts, and cytoprotection in the gut. Read the BPC-157 record for the actual mechanism, and read it knowing that BPC-157 itself has no human pharmacokinetic data.
Commonly researched ranges
- Clinic practice250–750 mcg
Clinics converge on 250–500 mcg once or twice daily, with some quoting 200–750 mcg a day. Where a source explains where the figures came from, the answer is the same every time: they are BPC-157’s numbers, carried across unchanged because the peptide is the same 15 amino acids in a different salt. No trial has ever dosed pentadeca arginate in a human. One clinic publishes the arithmetic in full: a 15 mg vial with 7.5 mL of bacteriostatic water gives 2 mg/mL, so 500 mcg is 25 units on a U-100 syringe. It is internally consistent, which is not the same as studied.
- Preclinical range (Paragon Sports Medicine)1–10 mcg/kg
× body weight in kg
Published as micrograms per kilogram from preclinical work, with the clinic stating plainly that no FDA-approved dosing guidelines exist for human use of PDA. Do not read this as a human dose.
| Phase | Amount | Frequency | Timing | Note |
|---|---|---|---|---|
| Clinic practice | 250–750 mcg | Once or twice daily, near the injury site, in 4–6 week cycles | Morning | Clinics converge on 250–500 mcg once or twice daily, with some quoting 200–750 mcg a day. Where a source explains where the figures came from, the answer is the same every time: they are BPC-157’s numbers, carried across unchanged because the peptide is the same 15 amino acids in a different salt. No trial has ever dosed pentadeca arginate in a human. One clinic publishes the arithmetic in full: a 15 mg vial with 7.5 mL of bacteriostatic water gives 2 mg/mL, so 500 mcg is 25 units on a U-100 syringe. It is internally consistent, which is not the same as studied. |
| Preclinical range (Paragon Sports Medicine) | 1–10 mcg/kg× body weight in kg | Not stated · preclinical | Not established in available literature | Published as micrograms per kilogram from preclinical work, with the clinic stating plainly that no FDA-approved dosing guidelines exist for human use of PDA. Do not read this as a human dose. |
- Cycle guidance
- Our sources publish no cycling schedule specific to pentadeca arginate. Community practice imports the BPC-157 pattern of 4–6 weeks with a break, which is convention rather than evidence.
- Goals
- Recovery, Gut
Where this sits with the FDA
FDA 503A bulks · treated as part of the BPC-157 family, whose nomination was withdrawn
The sales argument is that pentadeca arginate is a different substance from BPC-157 and therefore escapes the restriction. FDA evaluated BPC-157 free base and BPC-157 acetate together as BPC-157-related bulk drug substances, and its central objection at the July 2026 advisory meeting was that the identity is unsettled: no settled salt, ester or free base form. An arginate salt of the same pentadecapeptide sits inside that family, not outside it. The salt-based exemption argument has not been validated by any FDA guidance.
Last change · 22 April 2026 · BPC-157 and its salt forms came off Category 2 when the nomination was withdrawn, effective 22 April 2026.
Primary sourceWADA status
BPC-157 is named on the 2026 Prohibited List under S0. A different salt of the same peptide is the same peptide as far as an anti-doping laboratory is concerned.
The FDA reclassification has no effect whatsoever on WADA status. By our reading of the List, Pentadeca arginate stays S0 whether or not it lands on the 503A bulks list.
Mixing recipes our sources document
- 25 units500 mcg
- 50 units1 mg
No source we hold states a beyond-use window for this pairing, so we publish none. Go by what is printed on your own vial, and read the storage note below.
Week by week
Not established in available literature.
Side effects
Not established in available literature. Absence from this page does not mean absence of risk. It means our sources publish no side-effect profile for Pentadeca arginate.
Contraindications and interactions
Do not use if
- Read the BPC-157 record and apply it in full. PDA has no safety profile of its own because it has never been studied
- Known bleeding disorder or therapeutic anticoagulation: animal toxicity work on the underlying peptide showed altered clotting parameters
- Active or recent cancer: the underlying peptide is pro-angiogenic
Interactions
Not established in available literature.
Absence from this list does NOT mean safety. It means lack of research.
Storage and cost
- Storage
- Our sources do not publish a beyond-use window for reconstituted pentadeca arginate, so we publish none. The whole commercial argument for the arginate salt is better stability, and it is worth being precise about what the patent measured: chemical survival of the molecule in a tube under heat and acid. It did not measure how long a reconstituted vial stays sterile, which is what a beyond-use date is actually about.
- Cost
- Not established in available literature
Stacks with
Pentadeca arginate in full
The whole record in one sentence
Pentadeca arginate is BPC-157 with arginine attached instead of acetate.
That is not a simplification. The peptide is GEPPPGKPADDAGLV in both cases: fifteen amino acids, same order, same molecule. What differs is the counterion, the small charged partner that a peptide is packaged with so it forms a stable solid. Change the counterion and you change how the powder behaves in a vial. You do not change what the peptide does in a person.
What is actually documented
One thing, and it is a patent. US Patent 9,850,282 B2, "Stable pentadecapeptide salts", assigned to Diagen d.o.o., inventor Rudolf Rucman, priority March 2013, granted December 2017. It claims salts of the pentadecapeptide with arginine, lysine and ornithine, with di-L-arginine at a 1:2 ratio as the preferred form. It carries stability data from the patentee's own laboratory:
- 50 °C at 65% relative humidity for 90 days: acetate 85.90% remaining, arginate 99.07%
- Aqueous solution held at 100 °C for one hour: acetate 56.80%, arginate 99.08%
- Simulated gastric juice at pH 3.0 for five hours: acetate 10.1%, arginate 84.9%
Those numbers are real and they point the same way. The arginate salt survives heat and acid better than the acetate.
What that is not
It is a patent, filed by a commercially interested party, not a peer-reviewed replicated study. It measures chemical survival of a molecule in a tube. It does not measure absorption, bioavailability, blood levels, or any clinical outcome. A compound can survive stomach acid perfectly and still never cross the gut wall.
The widely repeated claim that pentadeca arginate is "1,000 times more stable at pH 3.0" does not match the patent's own figure either: 84.9% against 10.1% is roughly 8.4 times, not a thousand. An independent April 2026 review notes that the 1,000-fold claim has not been published in any peer-reviewed journal and appears to originate from internal compounding vendor documentation.
Evidence specific to PDA as a molecule
None. A ClinicalTrials.gov query for pentadeca arginate returns zero registered studies. There is no PubMed study of PDA as a distinct molecule. Zero human studies, zero animal studies. Everything claimed for it is claimed on BPC-157's behalf, and BPC-157's own human efficacy evidence is a single 2005 conference abstract in 53 ulcerative colitis patients that did not reach statistical significance.
One marketing claim worth naming
A clinic page states that PDA has been designated by FDA as a regenerative or regenerative-stimulating agent. FDA has no such designation. It is not a category that exists. When a page invents a regulatory status for a compound, that tells you what else on the page has been checked.
Safety
Inherit the BPC-157 record entirely, including the three adverse-event reports on file, the animal toxicity findings of altered clotting parameters, and raised serum ALT, glucose and triglycerides in the same 28-day study. The clotting finding was activated partial thromboplastin time shortened in rats and prolonged in dogs. Do not read pentadeca arginate as having a cleaner safety profile than BPC-157. It has no profile at all, which is a different thing.
Why this record exists
Because "PDA" is being sold in 2026 as a next-generation successor, and the honest version is more useful: it is the same peptide, in a salt that holds up better on a shelf, with all of the same unanswered questions and one fewer year of anybody looking at it.
If the stability argument is what appeals to you, the interesting follow-on question is the oral route. The acid-survival data is the only reason to think an oral pentadeca arginate might behave differently from oral BPC-157, and nobody has tested that in anything.
Sources
- 1US Patent 9,850,282 B2 · Stable pentadecapeptide salts (Diagen d.o.o., inventor Rudolf Rucman, granted 26 December 2017)
- 2Superpower · Pentadeca peptide review, April 2026
- 3Paragon Sports Medicine · Pentadeca arginate (PDA)
- 4Wittmer Rejuvenation Clinic · What is PDA (vendor tier)
- 5FDA · BPC-157 briefing document for the Pharmacy Compounding Advisory Committee
- 6American Telehealth Review · PDA clinic dosing, 250–500 mcg once or twice daily (vendor tier, dose review 2026-08-17)
- 7Wittmer Rejuvenation Clinic · PDA treatment plan, the 200–750 mcg/day end of clinic practice (vendor tier, dose review 2026-08-17)
Every record in this library is free to read, and it stays free. Your own schedule, vials and log live in the app: Claritide for iPhone.